RAPP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
20.0M
Cost of Revenue
0
0
0
0
0
Gross Profit
20.0M
Operating Expenses
60.8M
+37.5%
44.2M
+14.8%
38.5M
+28.4%
30.0M
+1.7%
29.5M
R&D
51.4M
+57.2%
32.7M
+8.1%
30.3M
+35.8%
22.3M
-1.8%
22.7M
SG&A
9.4M
-18.3%
11.5M
+39.4%
8.3M
+7.1%
7.7M
+13.1%
6.8M
Operating Income
-60806000
-151.1%
-24215000
+37.1%
-38509000
-28.4%
-29986000
-1.7%
-29496000
EBITDA
-60594000
-152.6%
-23988000
+37.3%
-38244000
-28.6%
-29730000
-1.7%
-29244000
Net Income
-56615000
-185.1%
-19857000
+41.2%
-33763000
-25.4%
-26925000
-0.7%
-26732000
EPS (Basic)
$-1.19
-183.3%
$-0.42
+40.8%
$-0.71
+0.0%
$-0.71
+5.3%
$-0.75
EPS (Diluted)
$-1.19
-183.3%
$-0.42
+40.8%
$-0.71
+0.0%
$-0.71
+5.3%
$-0.75
Shares (Diluted)
47.5M
+0.5%
47.2M
+21.3%
38.9M
+2.6%
37.9M
+7.0%
35.4M
Rapport Therapeutics (RAPP) — Financials